(19)
(11) EP 2 824 108 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
12.07.2017 Bulletin 2017/28

(45) Mention of the grant of the patent:
19.04.2017 Bulletin 2017/16

(21) Application number: 13847102.4

(22) Date of filing: 06.03.2013
(51) International Patent Classification (IPC): 
C07H 15/252(2006.01)
A61K 31/7056(2006.01)
 C07H 19/044(2006.01)
A61P 35/00(2006.01)
(86) International application number:
PCT/CN2013/000233
(87) International publication number:
WO 2014/059740 (24.04.2014 Gazette 2014/17)

(54)

TETRACYCLIC ANTHRAQUINONE DERIVATIVES

TETRACYCLISCHE ANTHRACHINONDERIVATE

DÉRIVÉS D'ANTHRAQUINONE TÉTRACYCLIQUE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 06.03.2012 CN 201210055298

(43) Date of publication of application:
14.01.2015 Bulletin 2015/03

(73) Proprietor: TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD.
Xiqing Economic-Technological Development Area Tianjin 300385 (CN)

(72) Inventors:
  • ZHANG, Hesheng
    Tianjin 300457 (CN)
  • HUO, Aihong
    Tianjin 300457 (CN)
  • LI, Zhenzhong
    Tianjin 300457 (CN)

(74) Representative: Smith, Matthew et al
Mewburn Ellis LLP City Tower 40 Basinghall Street
London EC2V 5DE
London EC2V 5DE (GB)


(56) References cited: : 
WO-A1-2009/099741
 CN-A- 101 555 264
   
  • JÖRG B. ENGEL ET AL: "Targeted Therapy of Breast and Gynecological Cancers with Cytotoxic Analogues of Peptide Hormones", MOLECULAR PHARMACEUTICS, vol. 4, no. 5, 1 October 2007 (2007-10-01) , pages 652-658, XP055203726, ISSN: 1543-8384, DOI: 10.1021/mp0700514
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).